{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspart&page=7",
    "query": {
      "intervention": "Aspart",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 181,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspart&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspart&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T16:37:30.883Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04292535",
      "title": "Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin",
        "Exercise"
      ],
      "interventions": [
        {
          "name": "Placebo into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "20 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "40 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "60 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "80 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "100 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "120 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-06-15",
      "completion_date": "2020-02-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "East Lansing, Michigan",
      "locations": [
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04292535"
    },
    {
      "nct_id": "NCT00581867",
      "title": "Memory and Insulin in Early Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Insulin Aspart",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeff Burns, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2007-10",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2015-07-14",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00581867"
    },
    {
      "nct_id": "NCT01464099",
      "title": "Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-06",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464099"
    },
    {
      "nct_id": "NCT05946785",
      "title": "Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Gestational Diabetes",
        "Vascular Endothelial Function"
      ],
      "interventions": [
        {
          "name": "Acetylcholine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anna Stanhewicz, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2023-07-01",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05946785"
    },
    {
      "nct_id": "NCT00797823",
      "title": "Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin, Asp(B28)-",
          "type": "DRUG"
        },
        {
          "name": "Glucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Legacy Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2008-11",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2011-10-07",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00797823"
    },
    {
      "nct_id": "NCT00361907",
      "title": "Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Effect of Pulsatile IV insulin on diabetic pt blood markers",
          "type": "PROCEDURE"
        },
        {
          "name": "Effect of Pulsatile IV Insulin on blood markers",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Florida Atlantic University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 105,
      "start_date": "2005-02",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Boca Raton, Florida",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00361907"
    },
    {
      "nct_id": "NCT00309244",
      "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 677,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 80,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309244"
    },
    {
      "nct_id": "NCT01269034",
      "title": "New Onset Type 1 Diabetes: Role of Exenatide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Rapid and long acting insulin",
          "type": "DRUG"
        },
        {
          "name": "long acting insulin + rapid acting + 1.25 mcg Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 13,
      "start_date": "2010-12",
      "completion_date": "2017-01-31",
      "has_results": true,
      "last_update_posted_date": "2021-08-04",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01269034"
    },
    {
      "nct_id": "NCT03511521",
      "title": "Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperglycemia Steroid-induced",
        "Insulin Resistance, Diabetes"
      ],
      "interventions": [
        {
          "name": "NPH Insulin",
          "type": "DRUG"
        },
        {
          "name": "glargine",
          "type": "DRUG"
        },
        {
          "name": "Insulin Aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2018-03-27",
      "completion_date": "2019-08-15",
      "has_results": true,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03511521"
    },
    {
      "nct_id": "NCT04409587",
      "title": "Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mountain Diabetes and Endocrine Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2018-04-12",
      "completion_date": "2020-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-23T16:37:30.883Z",
      "location_count": 1,
      "location_summary": "Asheville, North Carolina",
      "locations": [
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409587"
    }
  ]
}